▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #965 by analyst upside · 2026-10-23
IRLA
IRulya Therapeutics Inc.
Healthcare · Market Cap $33M · P/E 0x
ANALYST PRICE TARGET
+128.4%
implied upside to consensus target
Current Price $32.83
Consensus Target $75.0
Bull Target $98.0
Bear Target $65.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
1
Sell
0
52-Week Low $15.1
52-Week High $910.0
YTD Return -94.5%
FUNDAMENTALS
Market Cap $33M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-200.93
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.1
52-Week High $910.0
Current Price $32.83
Bear Target $65.0
Bull Target $98.0
● Now $32.83 ● Target $75.0
TRADING DATA
Avg Volume 39K
YTD Return -94.5%
Analyst Count 8
Consensus Buy
Upside to Target +128.4%
Last Updated 2026-10-23

ANALYST SUMMARY

IRulya Therapeutics Inc. (IRLA) is currently trading at $32.83 with a Wall Street consensus price target of $75.0, implying potential upside of 128.4% over the next 12 months. 8 analysts currently cover IRLA, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $98.0, while the most cautious has a target of $65.0.

IRLA operates in the Healthcare sector with a market capitalisation of $33M. The stock is down 94.5% year-to-date and is currently trading near the lower end of its 52-week range of $15.1 – $910.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IRLA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Raymond James ● Initiated
Outperform 2026-10-09 Building track record
Rodman & Renshaw ● Initiated
Buy 2026-09-24 29% win rate (7 calls)
Citizens ↑ Upgrade
Market Perform → Market Outperform 2026-09-22 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-08-18 40% win rate (10 calls)
Oppenheimer ● Initiated
Outperform → Outperform 2026-07-29 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2026-06-24 29% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-06-23 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
17/30
Consensus clarity
10/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →